Scholars Central

Conference abstractPublished 3 Oct 2016

Obesity in post-menopausal women starting adjuvant aromatase inhibitors for breast cancer: Is there an effect of body mass index on outcome?

Authors: Jamal Zekri, Kamel Farag, Ahmed Allithy

AlFaisal University, Saudi Arabia King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Aromatization of androgens accounts for the peripheral formation of significant proportion of estrogen. For this reason, aromatase inhibitors (AIs) including letrzole are standard adjuvant treatments for post-menopausal (PM) women with hormone receptor positive (HR+) breast cancer (BC). Aromatase enzyme activity is predominant in adipose tissue. This has led to speculation that aromatase activity is elevated in obese women and subsequently decreased clinical activity of AIs. In Saudi Arabia, 80% of women with BC are overweight, obese or morbidly obese. Results of international studies investigating the effect of body mass index (BMI) on clinical outcome of women with BC on adjuvant AIs are not conclusive. Certainly, there are no such studies in women from Saudi Arabia. Patients and Methods: The electronic records of consecutive 320 PM women with HR+BC starting adjuvant letrozole between January 2005 and December 2014 were retrospectively reviewed. Individual patientsâÂ?Â? data were extracted including: BMI on day of starting letrozole, patientsâÂ?Â? and tumorsâÂ?Â? characteristics and disease outcome. The co-primary endpoints are (1) Frequency of obesity in this population (2) Comparing relapse free survival (RFS) in non-obese (Group 1: G1; BMI < 30) and obese (Group 2: G2; BMI âÂ?¥ 30) patients. Results: One hundred patients (31.25%) were not obese (BMI < 35). Obesity (BMI âÂ?¥ 30) and morbid obesity (BMI âÂ?¥ 35) are present in 105/320 (32.8%) and 115/320 (35.9%) patients respectively. Known poor prognostic factors including larger tumor size, higher tumor grade and number on involved lymph nodes were associated with shorter RFS (Log Rank; P=0.004, 0.037 and <0.0001 respectively). RFS at 5 years (G1: 75% vs. G2: 90%) and at 8 years (G1: 69% vs. G2: 87%). Median RFS was not reached in both groups (Log Rank; P=0.097). Conclusion: About two thirds of PM women starting adjuvant AIs for BC are classified as obese. In this cohort, obesity did not adversely affect benefit from adjuvant letrozole. Larger cohort is needed to confirm this result.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Jamal Zekri”
  • BylineArticles whose byline prints “Kamel Farag”
  • BylineArticles whose byline prints “Ahmed Allithy”